Achiko AG (XSWX:ACHI) Short-Term Capital Lease Obligation : CHF0.00 Mil (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Achiko AG Short-Term Capital Lease Obligation?

Achiko AG's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2022 was CHF0.00 Mil.

Achiko AG Short-Term Capital Lease Obligation Historical Data

The historical data trend for Achiko AG's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Short-Term Capital Lease Obligation Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Short-Term Capital Lease Obligation

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial			-	-	-	-	-

Achiko AG Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Achiko AG Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Achiko AG's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (XSWX:ACHI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines